Recommendations of the Spanish Society of Paediatric Cardiology and Congenital Heart Disease as regards the use of drugs in attention deficit hyperactivity disorder in children and adolescents with a known heart disease, as well as in the general paediatric population: position statement by the Spanish Paediatric Association

• Autores principales: Javier Pérez-Lescure Picarzo (Autor), Fernando Centeno Malfaz (Autor), David Crespo Marcos (Autor), Rosa Collell Hernández (Autor), Teresa Fernández Soria (Autor), Begoña Manso García (Autor), Henar Rojo Sombrero (Autor), Anna Sabaté Rotés (Autor), Georgia Sarquella-Brugada (Autor)
• Formato: Libro
• Publicado: Elsevier, 2020-02-01T00:00:00Z.
• Materias: article
• Acceso en línea: Connect to this object online.

Introduction: Approved drugs for attention deficit hyperactivity disorder (ADHD) in Spain are methylphenidate, lisdexamphetamine, atomoxetine and guanfacine. Due to adverse cardiovascular effects, mainly increased blood pressure and heart rate, its use in patients with known or undiagnosed heart dis...